Global Computational Biology Market: Forecast to 2034

Table of Content

1. Executive Summary

2. Market Analysis
2.1. Market size and growth rates
2.2. Macroeconomic change
2.3. Market growth drivers, market dynamics and trends
2.4. Megatrends and their impact
2.5. Value chain analysis
2.6. Market scenarios and opportunity forecasts
2.7. Relevant markets
2.8. The new frontiers of growth
2.9. Creating value through sustainable strategies

3. Sentiment Analysis
3.1. Internal Friction Analysis: Where workflows are failing
3.2. Budgetary Pivot: Spending intent for next 12 months
3.3. Unmet ROI: Where current solutions are failing
3.4. Risk Aversion: Board-level fears regarding adoption
3.5. Legacy Debt: Technology replacement timelines
3.6. Social Proof: Competitive admiration benchmarking
3.7. Future-Skilling: Labor market shifts and obsolescence
3.8. Decision Maker Psychology: Selection vs. Rejection criteria
3.9. Price Elasticity: The “Too Cheap to Trust” floor
3.10. The Unasked Question: Emerging industry blind spots

4. Market Breakdown by Tool
4.1. Introduction
4.2. Analysis software and services
4.3. Databases
4.4. Hardware

5. Market Breakdown by Application
5.1. Introduction
5.2. Cellular & biological simulation
5.2.1. Computational genomics
5.2.2. Computational proteomics
5.2.3. Pharmacogenomics
5.2.4. Other simulations
5.3. Drug discovery & disease modelling
5.3.1. Target identification
5.3.2. Target validation
5.3.3. Lead discovery
5.3.4. Lead optimization
5.4. Preclinical drug development
5.4.1. Pharmacokinetics
5.4.2. Pharmacodynamics
5.5. Clinical trials
5.5.1. Phase I
5.5.2. Phase II
5.5.3. Phase III
5.5.4. Phase IV
5.6. Human body simulation software

6. Market Breakdown by Services
6.1. Introduction
6.2. Contract
6.3. In-house

7. Market Breakdown by End Use
7.1. Introduction
7.2. Commercial
7.3. Academics & research
8. Market Breakdown by Geography

8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Sweden
8.3.7. Switzerland
8.3.8. Netherlands
8.3.9. Others
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. South Korea
8.4.4. India
8.4.5. Australia
8.4.6. Others
8.5. Middle East & Africa
8.5.1. South Africa
8.5.2. Saudi Arabia
8.5.3. UAE
8.5.4. Israel
8.5.5. Others

9. Competitive Landscape
9.1. Competitive situation and trends
9.2. Industry benchmarking
9.3. Maintaining current market share
9.4. Expansion path
9.5. Recent market and industry developments
9.5.1. New product developments and announcements
9.5.2. Agreements, partnerships, joint ventures, and collaborations
9.5.3. Mergers and acquisitions and major PE deals

10. Companies Profiled
10.1. aganitha
10.2. Atomwise
10.3. Benevolent AI
10.4. BIODIGITAL
10.5. BIO-RAD
10.6. cadence
10.7. CERTARA
10.8. compugen
10.9. Dassault Systemes
10.10. deep genomics
10.11. DNAnexus
10.12. fios GENOMICS
10.13. Genedata (Danaher)
10.14. Illumina
10.15. instem
10.16. QIAGEN
10.17. Schrödinger
10.18. Thermo Fisher Scientific

Request Sample

Buy Now